Wealth management firm Douglas Lane & Associates bought 16,745 shares of Thermo Fisher Scientific for around $7.8 million, bringing their total holdings to 216,276 shares valued at $104.9 million. Thermo Fisher now represents 1.5% of their assets under management as of September 30, 2025. The company’s top holdings include NVIDIA, Alphabet, JPMorgan Chase, Microsoft, and Qualcomm. Thermo Fisher’s stock price was at $534.68 on October 9, 2025, down 12% over the past year. The company offers a range of life sciences solutions, analytical instruments, and biopharma services, with revenue diversified across different sectors.

Douglas Lane’s increased investment in Thermo Fisher suggests confidence in the stock’s value, especially after a decline in the past year. Thermo Fisher has shown strong business performance, with revenue growing by 3% in the second quarter of 2025. The company also raised its fiscal guidance for 2025 to around $44 billion in sales. With a reasonable price-to-earnings ratio and positive revenue and earnings growth, Thermo Fisher remains an attractive investment option. JPMorgan Chase is an advertising partner of Motley Fool Money.

Read more at Nasdaq: Financial Management Company Douglas Lane Raised Its Thermo Fisher Stake. Is the Stock a Buy?